Research article · 10 Mar 2019
Conference abstractPublished 15 Aug 2016
A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) Intensity Modulated Radiation Therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute
King Chulalongkorn Memorial Hospital, Thailand
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: To investigate acute and late toxicities comparing sequential (SEQ-IMRT) versus Simultaneous Integrated Boost- Intensity Modulated Radiotherapy (SIB-IMRT) in Naso Pharyngeal Carcinoma (NPC) patients. Methods: Newly diagnosed stage I-IVB NPC patients were randomized to receive SEQ-IMRT or SIB-IMRT, with or without chemotherapy. SEQ-IMRT consisted of two sequential radiation treatment plans: 2Gy x 25 fractions to low-risk planning target volume (PTV-LR) followed by 2Gy x 10 fractions to high-risk planning target volume (PTV-HR). In contrast, SIB-IMRT consisted of only one treatment plan: 2.12Gy and 1.7Gy x 33 fractions to PTV-HR and PTV-LR, respectively. Toxicities were evaluated according to CTCAE version 4.0. Results: Between October 2010 and November 2013, 122 eligible patients were randomized between SEQ-IMRT (54 patients) and SIB-IMRT (68 patients). With median follow-up time of 16.8 months, there was no significant difference in toxicities between the two IMRT techniques. During chemoradiation, the most common grade 3-5 acute toxicities were mucositis (15.4% vs 13.6%, SEQ vs SIB, p=0.788) followed by dysphagia (9.6% vs 9.1%, p=1.000) and xerostomia (9.6% vs 7.6%, p=0.748). During the adjuvant chemotherapy period, 25.6% and 32.7% experienced grade 3 weight loss in SEQ-IMRT and SIB-IMRT (p=0.459). One-year overall survival (OS) and progression-free survival (PFS) were 95.8% and 95.5% in SEQ-IMRT and 98% and 90.2% in SIB-IMRT, respectively (p =0.472 for OS and 0.069 for PFS). Conclusion: This randomized, phase II/III trial comparing SIB-IMRT versus SEQ-IMRT in NPC showed no statistically significant difference between both IMRT techniques in terms of acute adverse events. Short-term tumor control and survival outcome were promising.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Article · 25 Oct 2021
Dosimetric evaluation of vmat and imrt sssw treatment in simultaneous integrated boost sib plans for prostate cancer in
Research article · 2021
Dosimetric evaluation of VMAT and IMRT (SS/SW) treatment in Simultaneous Integrated Boost (SIB) plans for prostate cancer in Cheikh Zaid Hospital Oncology (Morocco)
Research article · 2012
Hypofractionated IMRT Breast Treatment with Simultaneous Versus Sequential Boost Techniques
Research article · 29 Apr 2021
SIB-IMRT radiotherapy concomitant with cisplatin in locally advanced hypopharyngeal cancer: safety, feasibility
More from this journal
The newest in Cancer Science & Therapy.
Commentary · 21 Feb 2026
Functional Immune Biomarker Identification in Patients with Breast Cancer
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Anussara P. Songthong”

